The myocardial protective effect of Danshen Dripping Pills in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention
ZHANG Yi FU Xiaolin LIU Bo TAN Hui LI Kang
Department of Intensive Medicine, Xianyang Central Hospital, Shaanxi Province, Xianyang 712000, China
Abstract:Objective To study the protective effect of Danshen Dripping Pills in patients with ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods A total of 109 patients with STEMI in Xianyang Central Hospital of Shaanxi Province from January 2014 to March 2016 were enrolled in this study. The subjects were randomly divided into the control group (54 cases) and the treatment group (55 cases) by the random number table method. All the patients were treated with PCI, and then the control group was treated with Atorvastatin Calcium, the treatment group was treated with Danshen Dripping Pills on basis of the control group. The two groups were treated for 3 months. The levels of serum cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), brain natriuretic peptide (BNP), interleukin 6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), nitric oxide (NO), endothelin (ET) and soluble adhesion molecules-1 (sICAM-1) of the two groups before and after treatment were compared and detected. The adverse cardiovascular events of the two groups after discharge for 2 years were compared. Results After treatment, the levels of serum cTnI, CK-MB and BNP of the control group were significantly higher than before treatment, the levels of serum cTnI, CK-MB and BNP of the treatment group were significantly lower than before treatment, and the levels of serum cTnI, CK-MB and BNP of the treatment group were significantly lower than the control group (P < 0.05). After treatment, the levels of serum IL-6, CRP, TNF-α, ET and sICAM-1 of the two groups were significantly lower than before treatment, the serum NO of the two groups was significantly higher than before treatment, and the level changes of serum IL-6, CRP, TNF-α, ET, sICAM-1 and NO in treatment group were better than those of the control group (P < 0.05). There was no significant difference of the rates of adverse cardiovascular events of the two groups during the follow-up period of 2 years (P > 0.05). Conclusion Based on the application of statins, Danshen Dripping Pills in STEMI patients after PCI has strong cardioprotective effect. It can reduce the inflammatory reactions and vascular endothelial injury induced by surgery, with good prognosis, and it is worthy of clinical application.
张怡 伏晓琳 刘博 谭辉 李康. 丹参滴丸对急性ST段抬高型心肌梗死PCI术后心肌保护作用[J]. 中国医药导报, 2018, 15(34): 153-156,160.
ZHANG Yi FU Xiaolin LIU Bo TAN Hui LI Kang. The myocardial protective effect of Danshen Dripping Pills in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention. 中国医药导报, 2018, 15(34): 153-156,160.